Bellicum Pharmaceuticals, Inc. (BLCM) Receives Average Rating of “Hold” from Analysts
Shares of Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) have been assigned an average recommendation of “Hold” from the eight brokerages that are currently covering the firm, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation and five have given a buy recommendation to the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $26.20.
A number of equities research analysts have weighed in on the company. Raymond James Financial, Inc. set a $18.00 price objective on Bellicum Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, August 9th. Cantor Fitzgerald reiterated an “overweight” rating and set a $35.00 target price on shares of Bellicum Pharmaceuticals in a research note on Monday, June 26th. BidaskClub downgraded shares of Bellicum Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, July 6th. Wells Fargo & Company reissued an “outperform” rating and set a $31.00 price target on shares of Bellicum Pharmaceuticals in a research report on Tuesday, June 27th. Finally, Jefferies Group LLC restated a “buy” rating and issued a $16.00 price target (down previously from $18.00) on shares of Bellicum Pharmaceuticals in a research note on Thursday, August 10th.
ILLEGAL ACTIVITY WARNING: “Bellicum Pharmaceuticals, Inc. (BLCM) Receives Average Rating of “Hold” from Analysts” was originally published by American Banking News and is the sole property of of American Banking News. If you are reading this article on another site, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The legal version of this article can be read at https://www.americanbankingnews.com/2017/10/04/bellicum-pharmaceuticals-inc-blcm-receives-average-rating-of-hold-from-analysts.html.
Shares of Bellicum Pharmaceuticals (NASDAQ:BLCM) opened at 11.29 on Wednesday. The firm has a 50-day moving average price of $10.21 and a 200-day moving average price of $11.58. The firm’s market capitalization is $375.12 million. Bellicum Pharmaceuticals has a 1-year low of $7.41 and a 1-year high of $23.11.
Bellicum Pharmaceuticals (NASDAQ:BLCM) last announced its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.74) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.65) by ($0.09). Bellicum Pharmaceuticals had a negative return on equity of 70.74% and a negative net margin of 17,957.31%. During the same period in the previous year, the business earned ($0.61) EPS. On average, analysts forecast that Bellicum Pharmaceuticals will post ($3.02) EPS for the current fiscal year.
In other news, VP Ken Moseley sold 13,823 shares of the firm’s stock in a transaction dated Thursday, July 13th. The shares were sold at an average price of $12.26, for a total value of $169,469.98. Following the transaction, the vice president now directly owns 14,314 shares in the company, valued at approximately $175,489.64. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider David M. Spencer sold 10,000 shares of the firm’s stock in a transaction dated Monday, July 10th. The stock was sold at an average price of $11.54, for a total transaction of $115,400.00. The disclosure for this sale can be found here. In the last quarter, insiders have sold 24,260 shares of company stock valued at $290,048. 18.77% of the stock is owned by insiders.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Teachers Advisors LLC boosted its stake in Bellicum Pharmaceuticals by 5.5% in the fourth quarter. Teachers Advisors LLC now owns 35,608 shares of the biopharmaceutical company’s stock valued at $485,000 after acquiring an additional 1,844 shares during the period. Wells Fargo & Company MN grew its holdings in shares of Bellicum Pharmaceuticals by 91.0% during the first quarter. Wells Fargo & Company MN now owns 76,081 shares of the biopharmaceutical company’s stock valued at $939,000 after purchasing an additional 36,242 shares during the last quarter. Bank of New York Mellon Corp grew its holdings in shares of Bellicum Pharmaceuticals by 1.0% during the first quarter. Bank of New York Mellon Corp now owns 95,934 shares of the biopharmaceutical company’s stock valued at $1,184,000 after purchasing an additional 935 shares during the last quarter. Swiss National Bank grew its holdings in shares of Bellicum Pharmaceuticals by 51.2% during the first quarter. Swiss National Bank now owns 44,300 shares of the biopharmaceutical company’s stock valued at $547,000 after purchasing an additional 15,000 shares during the last quarter. Finally, Ameriprise Financial Inc. grew its holdings in shares of Bellicum Pharmaceuticals by 29.6% during the first quarter. Ameriprise Financial Inc. now owns 192,501 shares of the biopharmaceutical company’s stock valued at $2,375,000 after purchasing an additional 43,955 shares during the last quarter. Hedge funds and other institutional investors own 55.73% of the company’s stock.
Bellicum Pharmaceuticals Company Profile
Bellicum Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system.
Receive News & Ratings for Bellicum Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.